EMEA-003042-PIP01-21 - paediatric investigation plan

batiraxcept

Key facts

• Active substance:
  batiraxcept
• Therapeutic area:
  Oncology
• Decision number:
  P/0431/2021
• PIP number:
  EMEA-003042-PIP01-21
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  • Treatment of fallopian tube cancer
  • Treatment of ovarian cancer
  • Treatment of primary peritoneal cancer
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  29/10/2021
• Compliance check done:
  No

Decision

P/0431/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for batiraxcept, (EMEA-003042-PIP01-21)

Adopted Reference Number: EMA/532612/2021